Katalin Pungor

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 10

Top Topics

Bipolar Disorder

Ejection Fraction

Patient Reported Outcomes

Top Venues

Advances in therapy

Neuropsychiatric disease and treatment

Therapeutic advances in psychopharmacology

Patient preference and adherence

This page only lists publications with an associated author ORCID identifier.

Publications

Katalin Pungor, Jennifer Lee, Tom R Denee, Yerkebulan Kambarov, Riikka Nissinen, Kevin Ampeh, Marco Pellegrini, Francesco Parmeggiani
Impacts of X-linked Retinitis Pigmentosa and Patient Pathways in European Countries: Results from the Cross-sectional EXPLORE XLRP-1 Physician Survey. Advances in therapy 41 (8) (2024)
Katalin Pungor, Jennifer Lee, Tom R Denee, Yerkebulan Kambarov, Riikka Nissinen, Kevin Ampeh, Marco Pellegrini, Francesco Parmeggiani
Impacts of X-linked Retinitis Pigmentosa and Patient Pathways in European Countries: Results from the Cross-sectional EXPLORE XLRP-1 Physician Survey. Advances in therapy 41 (8) (2024)
Katalin Pungor, Jennifer Lee, Tom R Denee, Yerkebulan Kambarov, Riikka Nissinen, Kevin Ampeh, Marco Pellegrini, Francesco Parmeggiani
Impacts of X-linked Retinitis Pigmentosa and Patient Pathways in European Countries: Results from the Cross-sectional EXPLORE XLRP-1 Physician Survey. Advances in therapy (2024)
Katalin Pungor, Jennifer Lee, Tom R Denee, Yerkebulan Kambarov, Riikka Nissinen, Kevin Ampeh, Marco Pellegrini, Francesco Parmeggiani
Impacts of X-linked Retinitis Pigmentosa and Patient Pathways in European Countries: Results from the Cross-sectional EXPLORE XLRP-1 Physician Survey. Advances in therapy 41 (8) (2024)
Gang Li, Alexander Keenan, Mehmet Daskiran, Maju Mathews, Isaac Nuamah, Camille Orman, Kruti Joshi, Arun Singh, Annabelle Godet, Katalin Pungor, Srihari Gopal
Relapse and Treatment Adherence in Patients with Schizophrenia Switching from Paliperidone Palmitate Once-Monthly to Three-Monthly Formulation: A Retrospective Health Claims Database Analysis. Patient preference and adherence 15 (2021)
Maju Mathews, Srihari Gopal, Arun Singh, Isaac Nuamah, Katalin Pungor, Wilson Tan, Bernardo Soares, Edward Kim, Adam J Savitz
Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Hoc Analysis of 3 Similarly Designed Randomized Studies. Neuropsychiatric disease and treatment 16 (2020)
Katalin Pungor, Vasilis P Bozikas, Robin Emsley, Pierre Michel Llorca, Srihari Gopal, Maju Mathews, Annette Wooller, Paul Bergmans
Stable patients with schizophrenia switched to paliperidone palmitate 3-monthly formulation in a naturalistic setting: impact of patient age and disease duration on outcomes. Therapeutic advances in psychopharmacology 10 (2020)
Martin Lambert, Pedro M Sanchez, Paul Bergmans, Srihari Gopal, Maju Mathews, Annette Wooller, Katalin Pungor
Effect of Paliperidone Palmitate 3-Month Formulation on Goal Attainment and Disability After 52 Weeks' Treatment in Patients with Clinically Stable Schizophrenia. Neuropsychiatric disease and treatment 16 (2020)
Maria Paz Garcia-Portilla, Pierre Michel Llorca, Giuseppe Maina, Vasilis P Bozikas, Halise Devrimci-Ozguven, Sung-Wan Kim, Paul Bergmans, Irina Usankova, Katalin Pungor
Symptomatic and functional outcomes after treatment with paliperidone palmitate 3-month formulation for 52 weeks in patients with clinically stable schizophrenia. Therapeutic advances in psychopharmacology 10 (2020)
Srihari Gopal, Jagadish Gogate, Katalin Pungor, Edward Kim, Arun Singh, Maju Mathews
Improvement of Negative Symptoms in Schizophrenia with Paliperidone Palmitate 1-Month and 3-Month Long-Acting Injectables: Results from a Phase 3 Non-Inferiority Study. Neuropsychiatric disease and treatment 16 (2020)